Literature DB >> 22048568

[Antipsychotic medications for bipolar I disorders. New atypical neuroleptic drug asenapine approved].

G Juckel1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22048568     DOI： 10.1007/s00115-011-3379-3

Source DB:  PubMed          Journal:  Nervenarzt        ISSN： 0028-2804            Impact factor:   1.214


× No keyword cloud information.
  11 in total

1.  Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study.

Authors:  Roger S McIntyre; Miriam Cohen; Jun Zhao; Larry Alphs; Thomas A Macek; John Panagides
Journal:  J Affect Disord       Date:  2010-11       Impact factor: 4.839

2.  Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia.

Authors:  John M Kane; Michael Cohen; Jun Zhao; Larry Alphs; John Panagides
Journal:  J Clin Psychopharmacol       Date:  2010-04       Impact factor: 3.153

3.  Long-term assessment of Asenapine vs. Olanzapine in patients with schizophrenia or schizoaffective disorder.

Authors:  J Schoemaker; D Naber; P Vrijland; J Panagides; R Emsley
Journal:  Pharmacopsychiatry       Date:  2010-03-04       Impact factor: 5.788

Review 4.  Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials.

Authors:  Ayşegül Yildiz; Eduard Vieta; Stefan Leucht; Ross J Baldessarini
Journal:  Neuropsychopharmacology       Date:  2010-10-27       Impact factor: 7.853

5.  A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states.

Authors:  Roger S McIntyre; Miriam Cohen; Jun Zhao; Larry Alphs; Thomas A Macek; John Panagides
Journal:  Bipolar Disord       Date:  2009-11       Impact factor: 6.744

6.  Asenapine versus olanzapine in acute mania: a double-blind extension study.

Authors:  Roger S McIntyre; Miriam Cohen; Jun Zhao; Larry Alphs; Thomas A Macek; John Panagides
Journal:  Bipolar Disord       Date:  2009-10-14       Impact factor: 6.744

7.  Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial.

Authors:  Roger S McIntyre; Miriam Cohen; Jun Zhao; Larry Alphs; Thomas A Macek; John Panagides
Journal:  J Affect Disord       Date:  2010-01-22       Impact factor: 4.839

8.  Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial.

Authors:  Steven G Potkin; Miriam Cohen; John Panagides
Journal:  J Clin Psychiatry       Date:  2007-10       Impact factor: 4.384

Review 9.  Asenapine.

Authors:  Juliane Weber; Paul L McCormack
Journal:  CNS Drugs       Date:  2009-09       Impact factor: 5.749

10.  Asenapine: a novel psychopharmacologic agent with a unique human receptor signature.

Authors:  M Shahid; G B Walker; S H Zorn; E H F Wong
Journal:  J Psychopharmacol       Date:  2008-02-28       Impact factor: 4.153
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.